A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 137 participants.
Also called NCT04308590
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 137 participants
- Sponsor
- Registry
-
NCT04308590
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Austria, Bulgaria, Germany, Israel, Italy, Poland, Romania, Spain
- Registry status
- Completed
Technical summary
Registry record NCT04308590. Randomized; triple masking; primary purpose treatment. Start 2020-07-27 (actual); primary completion 2024-09-19 (actual). Results posted on 2025-08-03.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas
- Acronym
- GRADIENT
- Condition
- Hypercortisolism
- Intervention (Drug)
- Relacorilant
- Intervention (Other)
- Placebo
- Lead sponsor
- Corcept Therapeutics
Record details
- Record id
cardio:ct-nct04308590- Content hash
c7ab0f2b19a1cfed82c19e52c0d0bbecc17fdd3a0f577db7f8b948eb6a5615a2